Background: Cancer registries play a fundamental role in cancer control and multicenter collaborative research. Recently, the need for reassessment of cancer registry criteria has arisen due to the newly released 2010 World Health Organization (WHO) classification. Accordingly, development of new coding guidelines for cancer is necessary to improve the quality of cancer registries, as well as to prevent conflicts that may arise when seeking medical insurance compensation. Methods: With funding from the Management Center for Health Promotion, 35 members of the Gastrointestinal Pathology Study Group and the Cancer Registration Committee of the Korean Society of Pathologists (KSP) participated in a second workshop for gastrointestinal tumor registration in Korea. Results: The topics of gastric epithelial tumor, colonic intramucosal carcinoma, neuroendocrine tumor (NET), gastrointestinal stromal tumor (GIST) and appendiceal mucinous tumor were discussed for new coding guidelines. A survey was then conducted among 208 members of the KSP for a consensus of the guidelines proposed in the workshop. Conclusions: Although a few issues were set aside for further discussion, such as coding for non-gastric GIST and some types of NET, the members agreed upon most of the proposed guidelines. Therefore, we suggest using the newly revised International Classification of Diseases for Oncology, 3rd edition (ICD-O-3) coding guidelines for registering gastrointestinal tumors in Korea.
of the important role of pathologists in classifying cancer be havior codes, the Gastrointestinal Pathology Study Group (GP SG) of the Korean Society of Pathologists (KSP) studied the coding of gastrointestinal cancers (gastric epithelial tumors, co lonic intramucosal cancers, neuroendocrine tumors [ carcinoid tumor ] , gastrointestinal stromal tumors [ GISTs ] and appendi ceal mucinous tumors), and subsequently published an article entitled, "Proposal for Creating a Guideline for Cancer Regis tration of the Gastrointestinal Tumors (I)," in the Korean Jour nal of Pathology in 2008. 1 The committee also published guide lines for coding microinvasive tumors of the ovary and breast in 2012. 2 In doing so, the committee provided a standardized plat form for pathologists to make better decisions regarding cancer behavior codes and for improving the quality of national cancer registry data in Korea. 1, 2 Recently, a need for reassessment of cancer registry criteria has arisen due to changes brought about with the newly released 2010 World Health Organization (WHO) classification 3 and American Joint Committee on Cancer (AJCC) cancer staging criteria. 4 As differences between the newly released guidelines and the previously proposed guidelines set by the GPSG may lead to confusion in reporting cases with the central cancer reg istry, the formulation of new guidelines for the coding of cancer cases is warranted to improve the quality of cancer registries, as well as to prevent potential conflict that may arise when seek ing medical insurance compensation.
In Korea, the GPSG of the KSP is the leading authority on guidelines for the coding of gastrointestinal tumors. Therefore, their expert opinion was sought, along with support from the Health Promotion Fund and the Cancer Registration Commit tee of the KSP, to provide an updated proposal for the coding of gastrointestinal tumors. To do so, the workshop entitled, "Up dated Proposal for Creating Guidelines for Cancer Registration of Gastrointestinal Tumors (II)," was organized by the GPSG of the KSP, and a survey of members of the KSP regarding several of the topics discussed at the workshop was conducted.
In this study, we analyzed the results of the survey as well as the discussion points and results of the workshop to provide an updated proposal for the coding of gastrointestinal tumors in Korea.
MATERIALS AND METHODS
Behavior codes for cancer are classified according to the Inter national Classification of Diseases, 3rd edition (ICD3), 5 the fifth digit of which signifies biologic behavior. Behavior codes are listed in Table 1 .
Thirtyfive members of the GPSG of the KSP participated in the workshop entitled "Updated Proposal for Creating Guide lines for Cancer Registration of Gastrointestinal Tumors (II)." Differing opinions regarding behavior coding were discussed among the participating group after a lecture on the topics of gastric epithelial tumors, colonic adenoma, colonic intraepithe lial carcinoma, colonic intramucosal carcinoma, neuroendocrine tumors, GISTs, and appendiceal mucinous tumors. The conclu sions of the discussion were addressed by all participants, and suggestions for coding were put forth. The participants actively exchanged opinions on the differences between the 2010 WHO classification and the Korean classification in an attempt to reach a unified opinion. Based on the results of this workshop, we for mulated a questionnaire and conducted a survey of 208 mem bers of the KSP during the 63rd annual fall meeting of the KSP in 2011. After the survey, we analyzed their responses, and fur ther discussed differing opinions with members of the GPSG.
RESULTS

An update proposal for the coding of gastrointestinal tumors Gastric adenoma and adenocarcinoma
According to the previous proposal made by the GPSG of the KSP in 2008, gastric epithelial tumors were classified as follows: lowgrade adenoma was classified as /0, highgrade ad enoma was classified as /2, intramucosal carcinoma and invasive carcinoma were classified as /3. This classification directly corre sponded with the 2010 WHO classification. Hence, all mem bers of the KSP unanimously agreed that the 2008 proposal made by GPSG in regards to gastric epithelial tumors did not need modification. It was also recommended to use the histo logic criteria, which was suggested by the GPSG in 1997 6 and in 2011, 7 for diagnosis of each grade of gastric epithelial lesion. To increase the concordance rate of diagnosis among patholo gists, it was decided that the GPSG should educate pathologists and promote the use of upgraded diagnostic criteria. In addi tion to coding for cancer, an attempt was made to standardize representative diagnostic terms and to reduce confusion among physicians by identifying undesirable diagnostic terms and ex pressions. The use of the diagnostic term "low to highgrade adenoma" was not recommended; however, if pathologists were to insist on using it, it should be classified as /0. In cases of in traepithelial carcinoma or noninvasive intraglandular carcino ma, the term "highgrade adenoma/dysplasia" was recommend ed as the primary representative diagnostic term. It was also suggested that notation of additional pathologic findings or al ternative terms could be used as an addendum.
All participants of the workshop were unified in their opin ion regarding coding for epithelial tumors of the stomach. More over, further survey of coding for epithelial tumors of the stom ach during the 63rd annual fall meeting of the KSP was not conducted because the criteria mentioned in the first edition of the proposal and the 2010 WHO classification were in agree ment.
Colonic adenoma/intraepithelial carcinoma, intramucosal carcinoma, invasive carcinoma According to the first edition of the proposal made by GPSG in 2008, 1 lowgrade adenoma/dysplasia was classified as /0, high grade adenoma/dysplasia was classified as /2, intraepithelial car cinoma and intramucosal carcinoma were classified as /2 and in vasive carcinoma infiltrating beyond the submucosa was classi fied as /3. This classification was reaffirmed in the second edi tion without any modification because it corresponded well with the new WHO classification in 2010. 3 In the first edition, the behavior code for intramucosal carcinoma was proposed as /2, but there were differences of opinion between pathologists and physicians. 8 In a survey conducted in 2008, about 82% of the members of the KSP agreed that the behavior code for intramu cosal carcinoma should be /2, while approximately 94% of mem bers in 2011 agreed with this classification. Thus, we realized that a majority of the members agreed with the proposal made by GPSG. To date, a multicenter study and consensus meeting for determining the histologic criteria for diagnosing colonic epithelial tumors have not been conducted. Hence, there is an urgent need for such research. In the meantime, it was recom mended for the histological diagnosis of colonic epithelial tu mors to follow the criteria presented in 2006. 9 As in the case of gastric epithelial tumors, an attempt was made to standardize representative diagnostic terms and to re duce confusion among physicians by identifying undesirable diagnostic terms and expressions. It was concluded that "tubu lar adenoma with low to highgrade dysplasia" is an inappro priate representative diagnostic term. In such cases, use of the term "tubular adenoma with lowgrade dysplasia" was porposed, along with a classification of /0. Generally it is thought that the incidence of highgrade dysplasia is only 5% of all colonic ade noma. Accordingly, as discussed during the workshop, overdi agnosis of highgrade dysplasia should be avoided, and diagno sis of highgrade dysplasia using strict diagnostic criteria is de sired. The term "tubular adenoma with focal highgrade dys plasia" was also discerned to be inappropriate as a representative diagnostic term. If notation of this term is necessary, it was rec ommended that it should be noted separately, subsequent to di agnosis using the appropriate representative diagnostic term. Traditional serrated adenoma is coded according to the grade of dysplasia, as in tubular adenoma.
Similarly, a recommendation was made to use the term "tu bular adenoma with highgrade dysplasia or intraepithelial car cinoma" in place of the term "tubular adenoma with highgrade dysplasia and multiple areas of adenocarcinoma in situ". It was recommended to not use "adenocarcinoma in situ" as a represen tative diagnostic term, and instead should be separately noted in addition to using the more appropriate representative diag nostic term "highgrade dysplasia". Additionally, instead of the term "moderately differentiated adenocarcinoma confined to the lamina propria of the mucosa", the term "intramucosal carcino ma" was recommended as a more suitable representative diag nostic term. In accordance with the 2010 WHO classification, both of the terms "intramucosal carcinoma" and "highgrade dysplasia" can be categorized with the same behavior code (/2).
The result of the survey for colon/rectum epithelial tumors revealed that 98.6% of the members of the KSP agreed upon classifying lowgrade adenoma as /0, 98.6% agreed upon classi fying highgrade adenoma as /2, 99.5% agreed upon classifying intraepithelial carcinoma as /2 and 93.8% agreed upon classify ing intramucosal carcinoma as /2 (Table 2) . Notably, the classi fication of intramucosal carcinoma as /2 was confirmed at the subsequent meeting with the GPSG after the survey.
Neuroendocrine tumors of the gastrointestinal tract
In the 2008 guidelines, all gastrointestinal neuroendocrine , at least 50 fields evaluated in the areas of highest mitotic density. MIB1 antibody; % of 500-2,000 cells in the areas of highest nuclear labeling. GEP-NET, gastroenteropancreatic neuroendocrine tumors.
tumors (NET) excluding those of the appendix and rectum were classified as /3. NET of the appendix and rectum were classified as /1 in cases of well differentiated NET found inci dentally, mea suring less than 1 cm and showing no angioinva sion or surrounding tissue invasion. All other NETs of the ap pendix and rectum, excluding well differentiated NET, were classified as /3. However, since the implementation of the 2008 guidelines, the behavior pattern of NET has been shown to be influenced by the site of origin and differentiation of the tumor. Based on the 2010 WHO classification, NETs, except for the L cell type and tubular carcinoids, are to be subdivided according to the organ involved and classified as malignant tumors (/3) ( Table 3 ). In addition, as the 2000 WHO classification was in ordinately confusing and complex due to the inclusion of stage related information in the grading system, stagerelated infor mation was not included in the 2010 WHO classification, and a tumor grading system proposed by the European Neuroendo crine Tumor Society (ENETS) was adopted. Grading according to this system is divided into three tiers (G1, G2, G3) based on mitotic count and Ki67 index, the definitions of which are listed in Table 4 . For mitotic counting, a mitotic count observ ed in at least 50 high power field (HPF; 1 HPF, 2 mm 2 ) in the most active area is required, and for Ki67 index using MIB1 antibody, an observation of 5002,000 cells in the areas of stron gest nuclear labeling ("hot spot") is required. 10 Among the dis cussions at the GPSG workshop, there was general agreement with the 2010 WHO classification thereof. Nevertheless, it was also decided that the GPSG should provide further details re garding the ambiguities in the 2010 WHO classification. Ad ditionally, it was recommended that the term "carcinoid tumor" of the gastrointestinal tract and hepatobiliarypancreatic sys tem should be replaced by the term "well differentiated NET."
NETs of the stomach are mostly well differentiated, nonfunc tioning enterochromaffinlike (ECL) cell carcinoids, which can be categorized into three distinct types: type I, associated with autoimmune chronic atrophic gastritis; type II, associated with multiple endocrine neoplasia type I (MEN1) and ZollingerEl lison syndrome (ZES); and type III, sporadic. Nodules measur ing more than 0.5 mm and less than 0.5 cm with submucosal invasion are classified as "microcarcinoids", and nodules mea suring more than 0.5 cm are classified as "carcinoids". ECL cell NETs usually demonstrate lowgrade malignant behavior and involve a very good prognosis. The prognosis thereof has been reported to be especially good if the tumor is confined to the mucosa and submucosa, measures <1 cm in size with no angio invasion, is nonfunctioning and can be observed in chronic atro phic gastritis and MEN1/ZES. 11 In the previous guidelines proposed by the GPSG in 2008, all gastric NETs were classified as tumors showing malignant behavior (/3), regardless of size or type, and in the 2010 WHO classification, all gastric NET were also classified as /3 as well. However, it has been reported that ECL cell NETs (especially type I and type II), which show an excellent prognosis, com prise a large portion of gastric NETs. For this reason, controver sy exists as to whether all gastric ECL cell NETs should be clas sified as /3. In fact, even though ECL cell NETs were described as tumors showing lowgrade malignancy with the 2010 WHO classification, no specific classification was provided therefore. As the behavior code of /1 is typically indicative of uncertainty regarding whether a tumor is benign or malignant (borderline malignancy, low malignant potential, or uncertain malignant potential), suggestions as to whether it would be reasonable to histologically classify G1 type I and II ECL cell NET associated with hypergastrinemia as /1 have been proposed. Accordingly, among discussions at the GPSG workshop, it was proposed that histological G1 type I and II ECL cell NET associated hyper gastrinemia measuring <1 cm and showing no angioinvasion should be classified as /1 and that histological G1 type I and II ECL cell NET measuring more than 1 cm and histological G2 type I and II ECL cell NET should be classified as /3. Also, it was recommended that physicians should measure serum gas trin level because it is impossible to discern accurate coding without this information. In this regard, cases of histological G1 type I and II ECL cell NET lacking data concerning serum gastrin level were proposed to be classified as /3 ( Table 5 ).
The results of the survey for gastric NETs revealed that 94.2%
of the members of the KSP agreed upon the newly proposed criteria of coding G1 type I and II ECL cell NET as /1. How ever, 5.2% objected, stating that a tumor classified as /1, based on the proposed criteria, should instead be classified as /2 or /3. It was decided that further research on the national incidence of gastric NETs in Korea, as well as serum gastrin level, associa tion of autoimmune gastritis and the site of origin, should be conducted for accurate coding of gastric NETs (Table 6 ).
In the 2008 WHO guidelines, all NETs of the small intes tine were classified as malignant (/3). But in the 2010 WHO classification, NET of the L cell type were classified as /1, while all other NETs were classified as /3. During the discussion at the GPSG workshop, it was proposed that NET of the L cell type measuring less than 1 cm should be classified as /1, and all other NETs should be classified as /3 (Table 5 ). Subsequent sur vey of KSP members revealed that 94.2% of respondents agreed upon the criteria for classification of NET of the L cell type as /1, and 98.6% agreed upon the criteria for classification of all other NETs as /3. However, 5.3% of the respondents stated that NET of the L cell type should be classified as /3, according to the previous criteria (Table 6 ).
In the 2008 GPSG guidelines, NETs of the appendix, mea suring less than 1 cm, histological G1 and no angioinvasion were classified as /1, and NETs of the appendix that did not ful fill the above mentioned criteria were classified as /3. In the 2010 WHO classification, NETs of the appendix of L cell type, mea suring less than 1 cm and showing no angioinvasion are classi fied as /1, and those that do not fulfill the above mentioned cri teria are classified as /3. To date, however, there is no marker that can easily identify NET of the L cell type. Considering this, the participants in the workshop agreed upon the classifi cation of NETs of the appendix measuring less than 1 cm with out angioinvasion as /1, and all other NETs of the appendix greater than 1 cm with angioinvasion as /3 (Table 5 ). According to our survey, 97.6% of the participants agreed upon the crite ria for classification of NETs of the appendix as /1, and 97.6% of the participants agreed upon the criteria for classification of the NETs of the appendix that do not fulfill the above mention ed criteria as /3 (Table 6 ). In the 2008 GPSG guidelines, NETs of the colon/rectum measuring less than 1 cm, of histological G1, and showing no angioinvasion were classified as /1. All other NETs of the colon/ rectum that did not fulfill the above mentioned criteria were classified as /3. In the 2010 WHO classification, L cell type NETs of the colon/rectum were classified as /1. As previously stated, there is no marker that can easily identify NETs of the L cell type. Considering this situation and that the majority of NETs occurring in the rectum are of the L cell type, it was pro posed during the workshop that NETs of the colon/rectum mea suring less than 1 cm without angioinvasion should be classi fied as /1, and that all other NETs of the colon/rectum that do not fulfill the above mentioned criteria should be classified as /3. This proposal was the same as that specified in the 2008 GPSG guidelines. Notwithstanding, even if a particular NET is of the L cell type, it should be classified as /3 when a tumor measures more than 1 cm, has a histological grade of 2 or 3, or shows angioinvasion. The reason for this proposal is that such cases are at an increased risk for metastasis ( Table 5 ). The pres ence of angioinvasion can be identified through hematoxylin and eosin staining, and the performance of immunohistochem istry was proposed when necessary.
Our survey revealed that 97.6% of the respondents agreed upon the criteria for classification of NETs of the colon/rectum as /1, and 97.6% of the respondents agreed upon the criteria for /3 classification. However, NETs of the rectum measuring less than 1 cm, corresponding to classification /1, have been shown to metastasize to the lymph nodes in 3% of cases. 12 In fact, there were cases of NET of the rectum measuring less than 1 cm me tastasizing to the lymph node, and there were many opinions suggesting that the criteria for tumor size should be 0.5 cm. Accordingly, the participants in the GPSP workshop discussed the need for further study on such cases. Moreover, 2.4% of the respondents stated that tumors fulfilling the proposed criteria for classification as /1 should be classified as /3 (Table 6 ).
Hepato-biliary-pancreatic NETs
In the 2008 GPSG guidelines, NETs of the pancreas measur ing <2 cm in size, with <2 mitosis/10 HPF, showing no an gioinvasion and no invasion to the surrounding tissue were clas sified as /0, and NETs of the pancreas measuring ≥2 cm in size or with 210 mitosis/10 HFP or showing angioinvasion or peri neural invasion were classified as /1 (for uncertain behavior). All other NETs of the pancreas were classified as /3. In the 2010 WHO classification, classification of NETs of the pancreas as /0 and /1 was not described, and all NETs of the pancreas were classified as /3, except for nonfunctioning microadenoma mea suring <0.5 cm. During the discussion at the workshop, all participants agreed to follow the 2010 WHO classification (Ta 
ble 5).
The results of our survey revealed that 93.8% of the respon dents agreed upon the criteria proposed in the 2008 guidelines for classification of NETs of the pancreas as /0; however, 6.3% of the respondents disagreed. In regards to NETs of the pancre as previously classified as /1 and /2 according to the 2008 GPSG guidelines, most of the respondents (94.2% and 96.6%) stated that they should be classified as /3 in accordance with the new criteria ( Table 6 ).
Primary NETs of the hepatobiliary system are very rare. Be cause most NETs of the hepatobiliary system are metastatic (/6), WHO classification for primary NETs of the hepatobili ary system has not been established. In cases of NET of the gall bladder, there were no differences in behavior codes between the 2000 and 2010 WHO classifications; all NETs of the gallblad der except for tubular carcinoid (/1) should be classified as /3. Histological features of the tubular carcinoid are as follows: L cell differentiation, abundant stroma, tubular structure, unclear margins from the surrounding tissue and positivity for gluca gon and chromogranin B. 13 
Gastrointestinal stromal tumor
Since 2001, the selection of patients to receive Imatinib (a KIT inhibitor) in treatment of GISTs depending on risk of tu mor progression and metastasis has remained a significant issue as the KIT inhibitor was being used to treat GISTs. However it is quite difficult to predict the clinical course of tumors based on pathological findings alone. For this reason, GISTs were di vided into four distinct risk groups depending on mitotic count and tumor size, according to a National Institute of Health (NIH) consensus meeting (Table 7) .
14 In Korea, the 2008 GPSG guide lines were proposed on the basis of the NIH consensus meeting and data targeting Korean GIST patients provided by Kim et al. (Table 8) . 15 However, there were some problems and limitations with the application of the same criteria for the stomach to the duodenum/small intestine/colon, as the risk of malignancy is different for each organ. Furthermore, in the 2010 study target ing Korean GIST patients, tumor location in addition to size and mitosis were reported as important predictors of patient survival. 16 In the 2010 WHO classification, new criteria for risk classification were proposed according to the National Compre hensive Cancer Network (NCCN) guidelines on the basis of the criteria reported by Miettinen. 17, 18 Not surprisingly, the differ ences between the existing criteria and the new criteria have Table 7 . Diagnosis of GIST malignancy based on tumor size and mitosis for defining risk of aggressive behavior in GISTs (based on the NIH consensus meeting) 14 
Diagnosis
Size ( Values are presented as percentage. GIST, gastrointestinal stromal tumor; HPF, high power field; Insuff., insufficient. caused some confusion (Tables 9, 10 ). At the GPSG workshop, participants concluded that the re vised behavior codes put forward by the 2010 WHO classifica tion, based on the NCCN guidelines, according to the criteria set for risk classification of GIST, were not practical. Upon fur ther discussion of whether to follow the NCCN guidelines or the criteria of the NIH consensus meeting, the participants pro posed to classify all GIST risk groups in accordance with the currently implemented NIH criteria, but to revise the behavior codes of nongastric GIST as follows: very low risk nongastric GIST, previously classified as /0, should be classified as /1 and low risk nongastric GIST, previously classified as /1, should be classified as /3 (Table 8 ). According to our survey conducted af ter the workshop, 92.3% of the respondents agreed upon the criteria for classification of very low risk nongastric GIST as /1, and 84.1% agreed upon the criteria for classification of low risk nongastric GIST as /3. However, 7.2% of the respondents dis agreed upon classifying very low risk nongastric GIST as /1, and 13.9% disagreed upon classifying low risk nongastric GIST as /3 (Table 11 ). Moreover, 57.2% of the respondents answered that they would rather use the NIH criteria for the coding of gastric GIST, 40.9% responded that they would rather use the NCCN criteria, and 1.9% of the respondents answered that they would use would rather both of the criteria to code for gas tric GIST. In coding for nongastric GIST, 58.7% of the respon dents answered that they would rather use the NIH criteria, 39.4% responded that they would rather use the NCCN crite ria, and 1.9% of the respondents answered that they would like to use both criteria. Furthermore, considerable confusion regar ding the pathological diagnosis, application of the risk group and behavior codes, and cancer registry for GIST was identified. Thus, study of nationwide statistics and prognoses of Korean GIST patients is needed.
Appendiceal mucinous tumors
In the 2008 GPSG guidelines, mucinous tumors of the ap pendix were classified into four categories: mucinous cystadeno mas were classified as /0, mucinous neoplasms of uncertain ma lignant potential were classified as /1, mucinous neoplasms of low malignant potential (extremely well differentiated muci nous adenocarcinomas) were classified as /3, as were mucinous adenocarcinomas. In contrast, according to the 2010 WHO classification, mucinous tumors with lowgrade dysplasia are to be diagnosed as lowgrade appendiceal mucinous neoplasms (LAMN) and classified as /1. Moreover, mucinous tumors with focal highgrade dysplasia and a definite invasive pattern with desmoplastic stroma are to be diagnosed as mucinous adenocar cinomas and classified as /3. 3 In the new 2010 WHO classifica tion, mucinous tumors of the appendix are categorized into two groups based on nuclear dysplasia grade, and a new category "mucinous neoplasms of uncertain malignant potential" was created. Controversy exists concerning the classification of LA MN because of a lack of clarity on its invasiveness. In the new 2010 WHO classification, it was mentioned that LAMN can be differentiated from adenoma by a loss of the lamina propria and the presence of tumor cells in fibrous stroma.
In the GPSG workshop, participants agreed to accept the 2010 WHO classification regarding the classification and be havior coding of mucinous tumors of the appendix (Table 12) . And our survey revealed that 98.1% of respondents agreed upon the criteria for classification of mucinous tumors of the appendix as /1; no significant difference was seen from the 2008 GPSG guidelines (Table 13) .
According to the 7th edition of AJCC 4 and the 2010 WHO classification criteria, 3 appendiceal mucinous tumors that have ruptured but are still localized in the right lower quadrant or directly invading the surrounding tissue are to be classified as T4. Those that have widely spread into the peritoneal cavity are to be classified as pseudomyxoma peritonei (M1a). Pseudomyx oma peritonei was divided into lowgrade (G1) and highgrade (G2) depending on the dysplasia of tumor cells within it and was staged as IVA and IVB according to this grading. Accord ingly, participants in the GPSG workshop agreed that all pseu domyxoma peritonei should be classified as /6, and cases in which tumor cells were not detected within mucin pools should still be clinically considered as pseudomyxoma peritonei (/6). Dur ing the discussion at this workshop, it was mentioned that a tumor is more likely to have a poor prognosis in cases in which tumor cells are present within the mucin pool. Therefore, it was emphasized that pathology reports should include mention of the presence or absence of tumor cells within the mucin pool, in cases in which the mucinous neoplasm is located in the right lower quadrant or is directly invading the surrounding tissue (T4). It was also discussed that one should not overlook the fact that pseudomyxoma peritonei may also occur in other organs besides the appendix, as LAMN may develop into lowgrade pseudomyxoma peritonei due to metastasis. Accordingly, par ticipants discussed whether the behavior code of primary LAMN should be left unchanged as /1 or be changed to /3 in such cases. The participants ultimately concluded that primary LAMN should be given the behavior code of /1 and pseudomyxoma peritonei should be given the behavior code of /6, agreeing that this coding could adequately indicate malignancy of the tumor.
DISCUSSION
It is expected that the updated proposals put forward by the GPSG, including the contents of the present research, will fa cilitate the standardization of cancer registration and reduce confusion among pathologists for deciding on cancer registra tion codes, leading to more accurate cancer statistics in Korea. However, as behavior codes for a few NETs and GISTs are un der dispute, further discussion and research is needed to reach a consensus. Therefore, aggressive budget support will be needed for continuing education and research.
The results of survey of the members of the KSP revealed that the respondents' opinions generally coincided with those drawn from the GPSG workshop, regarding the newly revised behav ior codes for tumors. Also, there was strong agreement on the coding for high grade adenoma/dysplasia of the stomach and colon, as well as intramucosal carcinoma of the colon, which showed the lowest concordance rate in a previous report on the 2008 GPSG guidelines. However, among the newly revised guidelines, the concordance rate of coding for GIST was lowest in nongastric GIST and highest in gastric GIST, indicating a need for further discussion. Furthermore, diagnostic criteria for gastrointestinal epithelial tumors were not discussed in this work shop. Nevertheless, as differences in interpretation among phy sicians is bound to occur, further discussion and education on the diagnostic criteria and recommended use of representative diagnostic terms in order to avoid confusion with the cancer registry is needed. Regardless, based on the results of the work shop and subsequent survey, we encourage the use of the updat ed proposal for behavior coding of gastrointestinal tumors (Ap pendix 1). 
